EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
Commentary|Videos|September 8, 2025
How Primary Care Physicians Can Approach the Use of GLP-1 Receptor Agonists for Weight Loss
Author(s)Michael Crotty, MD, Sydney Jennings
Fact checked by: Grace Halsey
Michael Crotty, MD, provides practical guidance for on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan.
Advertisement
How can primary care physicians effectively incorporate glucagon-like peptide-1 (GLP-1) receptor agonists into a comprehensive obesity treatment plan? In the video above, Michael Crotty, MD, a general practitioner who specializes in obesity medicine, offers practical guidance on integrating GLP-1 receptor agonists into a comprehensive obesity treatment plan that complements lifestyle and behavioral interventions.
Dr Crotty is also the co-founder and clinical lead of
Advertisement
Related to this article
Endocrine Society statement highlights key research gaps on obesity drugs—who benefits, long-term dosing, safety, and measuring success beyond weight loss.
A new scientific statement calls for a shift in obesity management and treatment to focus on overall health improvements rather than just weight loss alone.
Semaglutide brought 40.4% of children below the obesity BMI threshold, according to top-line results from the phase 3 STEP Young clinical trial.
US clinicians increasingly prescribe GLP-1 drugs to young children with obesity, although overall use remains limited and access disparities persist.
Real-world phase 4 data show fezolinetant eases menopausal hot flashes and improves sleep, cutting nighttime awakenings by 2.6 by week 12.
September FDA news included updates in CKD and type 1 diabetes, major depressive disorder, insulin pump technology, alopecia areata, and more.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
Advertisement
Advertisement
Trending on Patient Care Online
1
5 FDA Decisions for Primary Care to Know from September 2026
2
Atrial Fibrillation Stroke Prevention: Expert Guidance for Primary Care Physicians
3
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
4
Fezolinetant Linked to 2.6 Fewer Nighttime Awakenings in Women With Menopausal VMS
5